Aptamer against insulin receptor and pharmaceutical compostion containing the same
US10724039B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 3, 2016 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Aug 3, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/62
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.